Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neuronetics Inc (STIM)

Neuronetics Inc (STIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,602
  • Shares Outstanding, K 69,277
  • Annual Sales, $ 149,160 K
  • Annual Income, $ -39,000 K
  • EBIT $ -31 M
  • EBITDA $ -28 M
  • 60-Month Beta 0.87
  • Price/Sales 0.70
  • Price/Cash Flow N/A
  • Price/Book 4.12

Options Overview Details

View History
  • Implied Volatility 232.54% (+43.11%)
  • Historical Volatility 111.42%
  • IV Percentile 71%
  • IV Rank 20.96%
  • IV High 728.52% on 03/13/26
  • IV Low 101.04% on 08/20/25
  • Expected Move (DTE 7) 0.3825 (27.72%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 117
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 6,370
  • Open Int (30-Day) 6,467
  • Expected Range 0.9975 to 1.7625

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 1
  • High Estimate $-0.17
  • Low Estimate $-0.17
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8000 +77.50%
on 03/17/26
1.8150 -21.76%
on 04/06/26
+0.2000 (+16.39%)
since 03/10/26
3-Month
0.8000 +77.50%
on 03/17/26
2.3100 -38.53%
on 01/23/26
-0.6500 (-31.40%)
since 01/09/26
52-Week
0.8000 +77.50%
on 03/17/26
4.8495 -70.72%
on 08/05/25
-2.3500 (-62.33%)
since 04/10/25

Most Recent Stories

More News
Neuronetics Comments on Letter from Pointillist Family Office

MALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve...

STIM : 1.3500 (-2.17%)
Neuronetics Announces Chief Financial Officer Transition

MALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve...

STIM : 1.3500 (-2.17%)
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business

STIM : 1.3500 (-2.17%)
Neuronetics: Q4 Earnings Snapshot

Neuronetics: Q4 Earnings Snapshot

STIM : 1.3500 (-2.17%)
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37%...

STIM : 1.3500 (-2.17%)
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve...

STIM : 1.3500 (-2.17%)
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare...

STIM : 1.3500 (-2.17%)
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth...

STIM : 1.3500 (-2.17%)
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare...

STIM : 1.3500 (-2.17%)
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...

STIM : 1.3500 (-2.17%)

Business Summary

Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics,...

See More

Key Turning Points

3rd Resistance Point 1.6183
2nd Resistance Point 1.5667
1st Resistance Point 1.4733
Last Price 1.3500
1st Support Level 1.3283
2nd Support Level 1.2767
3rd Support Level 1.1833

See More

52-Week High 4.8495
Fibonacci 61.8% 3.3026
Fibonacci 50% 2.8248
Fibonacci 38.2% 2.3469
Last Price 1.3500
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.